In a pregnant woman who is heterozygous for factor V Leiden and has no prior venous thrombo‑embolism or other risk factors, what is the recommended first‑line management to prevent VTE?

Management of Heterozygous Factor V Leiden in Pregnancy Without Prior VTE

For a pregnant woman who is heterozygous for factor V Leiden with no prior VTE and no additional risk factors, clinical surveillance alone is recommended during both the antepartum and postpartum periods—prophylactic anticoagulation is not indicated. 1

Antepartum Management

The American Society of Hematology (ASH) 2018 guidelines provide the clearest directive: regardless of family history of VTE, antepartum antithrombotic prophylaxis should NOT be used to prevent a first VTE in heterozygous factor V Leiden carriers. 1 This is a conditional recommendation based on very low certainty evidence, but it represents consensus across multiple major guideline bodies including the American College of Chest Physicians (ACCP), which similarly recommends antepartum clinical surveillance regardless of family history. 1

When to Consider Prophylaxis

Prophylactic anticoagulation during pregnancy should only be considered if additional risk factors are present, such as: 1, 2

• BMI ≥30 kg/m² at first antepartum visit
• Smoking >10 cigarettes per day antepartum
• Pre-eclampsia
• Intrauterine growth restriction
• Placenta previa
• Emergency cesarean section
• Peripartum blood loss >1 L or need for blood product replacement

The Royal College of Obstetricians and Gynecologists (RCOG) uses a weighted scoring system: prophylaxis throughout pregnancy should be considered with a score of ≥3, or from 28 weeks with a score of 2. 1

Postpartum Management

For women without a family history of VTE, the ASH guideline panel suggests against antithrombotic prophylaxis in the postpartum period. 1 This recommendation changes significantly based on family history and additional risk factors.

Risk Stratification for Postpartum Prophylaxis

If there is NO family history of VTE: Clinical surveillance alone is appropriate. 1, 2

If there IS a family history of VTE in a first-degree relative: Postpartum prophylaxis with prophylactic- or intermediate-dose LMWH (or vitamin K antagonists targeted at INR 2.0-3.0) for 6 weeks is recommended over routine care. 1

If two or more additional risk factors are present (from the list above), prophylaxis should be given for 6 weeks postpartum, even without family history. 1, 2

Choice of Anticoagulant When Indicated

When prophylaxis is warranted, low molecular weight heparin (LMWH) is the preferred agent during pregnancy due to ease of use, lower risk of adverse events, lack of need for monitoring, and safety during breastfeeding. 2 Prophylactic or intermediate dosing is appropriate depending on the clinical scenario. 1

Vitamin K antagonists are contraindicated during pregnancy due to teratogenicity but may be used postpartum during breastfeeding. 3

Critical Pitfalls to Avoid

• Do not initiate prophylactic anticoagulation based solely on heterozygous factor V Leiden status without prior VTE. The absolute risk in heterozygotes without additional factors is low (baseline postpartum VTE risk <1%). 4, 5

• Do not overlook the importance of family history. A first-degree relative with VTE before age 50 significantly changes postpartum management recommendations. 1

• Do not fail to reassess risk factors throughout pregnancy. New complications like pre-eclampsia or emergency cesarean section may warrant initiation of prophylaxis. 1

• Distinguish heterozygous from homozygous or compound heterozygous states. Homozygous factor V Leiden or combined heterozygosity (factor V Leiden plus prothrombin mutation) carries much higher risk (15-20% pregnancy-related VTE) and requires different management. 6, 5

Clinical Algorithm

1. Confirm heterozygous factor V Leiden status and absence of prior VTE
2. Assess family history: First-degree relative with VTE before age 50?
3. Screen for additional risk factors at each visit (obesity, smoking, pregnancy complications)
4. Antepartum: Clinical surveillance only, unless ≥2 additional risk factors develop
5. Postpartum:
   • No family history + no additional factors = clinical surveillance only 1
   • Family history present = LMWH prophylaxis for 6 weeks 1
   • ≥2 additional risk factors = LMWH prophylaxis for 6 weeks 1, 2

This conservative approach balances the low absolute risk of VTE in isolated heterozygous factor V Leiden (approximately 6.4% across all pregnancies, with most events postpartum) against the burden and bleeding risk of unnecessary anticoagulation. 5